Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $13.38

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has earned an average rating of "Buy" from the nine ratings firms that are currently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $13.38.

A number of research firms have issued reports on CMPX. Jefferies Financial Group increased their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. HC Wainwright reiterated a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a research note on Monday, April 21st. Leerink Partners raised shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. Finally, Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target on the stock.

Compass Therapeutics Stock Up 1.9 %

Shares of Compass Therapeutics stock traded up $0.04 on Friday, reaching $1.88. 127,797 shares of the stock were exchanged, compared to its average volume of 876,266. The business has a 50 day moving average price of $2.17 and a two-hundred day moving average price of $2.10. The firm has a market capitalization of $259.28 million, a price-to-earnings ratio of -5.07 and a beta of 1.40. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current year.

Insider Buying and Selling

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jonathan Anderman purchased 20,000 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was acquired at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the purchase, the insider now owns 21,000 shares in the company, valued at approximately $32,340. The trade was a 2,000.00 % increase in their position. The disclosure for this purchase can be found here. 28.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CMPX. Tower Research Capital LLC TRC boosted its holdings in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after purchasing an additional 12,917 shares during the period. Independent Advisor Alliance bought a new position in shares of Compass Therapeutics during the 4th quarter valued at $26,000. BNP Paribas Financial Markets bought a new position in Compass Therapeutics during the 4th quarter worth approximately $27,000. Mariner LLC bought a new stake in Compass Therapeutics during the 4th quarter valued at $30,000. Finally, Squarepoint Ops LLC bought a new position in Compass Therapeutics during the 4th quarter valued at approximately $35,000. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.